Sangamo Therapeutics’ (SGMO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report released on Wednesday, Benzinga reports. They currently have a $5.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on Sangamo Therapeutics in a report on Saturday, July 20th. They set a sell rating on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of Hold and a consensus target price of $5.67.

Sangamo Therapeutics Trading Up 28.7 %

Shares of NASDAQ SGMO opened at $0.86 on Wednesday. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.48. The stock has a 50 day moving average of $0.49 and a two-hundred day moving average of $0.61.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative return on equity of 182.55% and a negative net margin of 1,749.06%. The company had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $8.51 million. During the same quarter last year, the company earned $0.12 EPS. On average, equities research analysts forecast that Sangamo Therapeutics will post -0.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several large investors have recently added to or reduced their stakes in SGMO. Mackenzie Financial Corp lifted its position in Sangamo Therapeutics by 72.4% during the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 31,003 shares during the period. State Board of Administration of Florida Retirement System raised its holdings in shares of Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 23,650 shares during the period. Golden State Equity Partners grew its stake in Sangamo Therapeutics by 21.0% during the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 34,960 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Sangamo Therapeutics during the 1st quarter valued at approximately $331,000. Finally, Assenagon Asset Management S.A. grew its stake in Sangamo Therapeutics by 14.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 129,811 shares in the last quarter. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.